Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Gyre Therapeutics's price to sales ratio was 4.2× on Nov 11, 2026, against 6.3× a year earlier. Over the last 5 years it ranged from 4.2× to 434.9×, with a median of 10.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.2× | −1.5 |
| 2025 | Dec 31, 2025 | 5.7× | −4.2 |
| 2024 | Dec 31, 2024 | 9.9× | −114.1 |
| 2022 | Jul 29, 2022 | 124.0× | +80.4 |
| 2021 | Dec 31, 2021 | 43.5× | −57.1 |
| 2015 | Oct 30, 2015 | 100.7× | −320.2 |
| 2014 | Dec 31, 2014 | 420.9× | +382.3 |
| 2013 | Dec 31, 2013 | 38.6× | +36.4 |
| 2012 | Dec 31, 2012 | 2.2× | +0.1 |
| 2011 | Dec 30, 2011 | 2.1× | −28.9 |
| 2010 | Dec 31, 2010 | 30.9× | – |
See a number that looks wrong?